Chinese API Imports Eclipse Indian Plants

Indian firms have underscored growing concern around an ''over-dependence'' on Chinese active pharmaceutical ingredient (API) imports and the potentially crippling effect these could have on India's own essential drug supplies, should there be any turbulence in Indo-China relations.

A white paper by the Indian Drug Manufacturers Association (IDMA) refers to how imports of APIs and advanced intermediates have grown at a compound annual growth rate (CAGR) of 18% over the past decade from $800m in 2004 to $3.4bn currently, with China estimated to contribute around 58% of these imports by value.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

11 Apr 2025

• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

10 Apr 2025

• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

China Deal-Making Matures As Foreign Partners Derisk Asset Acquisition

09 Apr 2025

• By Xu Hu

Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.

Vocal For ‘Glocal’: How Menarini Is Adapting To Outperform In The Asia Pacific

08 Apr 2025

• By Anju Ghangurde

Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.